Pulse Biosciences Q1 net loss widens to $16.8M; cash $119.3M; clinical milestones set

PULSE BIOSCIENCES, INC.

GAAP net loss of $16.8M vs $10.1M in Q1 2024; non-GAAP net loss $11.4M vs $8.1M.
Cash and equivalents $119.3M as of March 31, 2025, down from $118.0M at Dec 31, 2024.
Costs and expenses $18.0M, up $7.4M YoY, driven by stock-based comp and organization expansion.
On track to launch nsPFA Percutaneous Electrode System in H2 2025; U.S. IDE for cardiac surgery and catheter systems expected mid-2025.
Treated 100 patients in Europe with nsPFA 360° catheter; data presented at HRS 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.